Roland Chapurlat

Roland Chapurlat

Auto-generated profile, based on publicly available information

Roland Chapurlat

INSERM UMR 1033, University of Lyon, Hospices Civils de Lyon, Lyon, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
HBHenry G Bone
Henry G Bone
RWRachel B Wagman
Rachel B Wagman
Maria Luisa BrandiMaria Luisa Brandi
Maria Luisa Brandi
JBJacques P Brown
Jacques P Brown
RCRoland Chapurlat
Roland Chapurlat
SPSocrates Papapoulos
Socrates Papapoulos

1 March 2017 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
TGthe IOF-ESCEO Sarcopenia Working Group
the IOF-ESCEO Sarcopenia Working Group
CBC. Beaudart
C. Beaudart
ADA. Dawson
A. Dawson
SSS. C. Shaw
S. C. Shaw
NHN. C. Harvey
N. C. Harvey
EDElaine Dennison
Elaine Dennison
Summary This systematic review summarizes the effect of combined exercise and nutrition intervention on muscle mass and muscle function. A total of 37 RCTs were identified. Results indicate that physical exercise has a positive impact on muscle mass and muscle function in subjects aged 65 years and older. However, any interactive effect of dietary supplementation appears to be limited. Introduction In 2013, Denison et al. conducted a systematic review including 17 randomized controlled trials (RCTs) to explore the effect of combined exercise and nutrition intervention to improve muscle mass, muscle strength, or physical performance in older people. They concluded that further studies were needed to provide evidence upon which public health and clinical recommendations could be based. The purpose of the present work was to update the prior systematic review and include studies published up to October 2015. Methods Using the electronic databases MEDLINE and EMBASE, we identified RCTs which assessed the combined effect of exercise training and nutritional supplementation on muscle strength, muscle mass, or physical performance in subjects aged 60 years and over. Study selection and data extraction were performed by two independent reviewers. Results The search strategy identified 21 additional RCTs giving a total of 37 RCTs. Studies were heterogeneous in terms of protocols for physical exercise and dietary supplementation (proteins, essential amino acids, creatine, β-hydroxy-β-methylbuthyrate, vitamin D, multi-nutrients, or other). In 79% of the studies (27/34 RCTs), muscle mass increased with exercise but an additional effect of nutrition was only found in 8 RCTs (23.5%). Muscle strength increased in 82.8% of the studies (29/35 RCTs) following exercise intervention, and dietary supplementation showed additional benefits in only a small number of studies (8/35 RCTS, 22.8%). Finally, the majority of studies showed an increase of physical performance following exercise intervention (26/28 RCTs, 92.8%) but interaction with nutrition supplementation was only found in 14.3% of these studies (4/28 RCTs). Conclusion Physical exercise has a positive impact on muscle mass and muscle function in healthy subjects aged 60 years and older. The biggest effect of exercise intervention, of any type, has been seen on physical performance (gait speed, chair rising test, balance, SPPB test, etc.). We observed huge variations in regard to the dietary supplementation protocols. Based on the included studies, mainly performed on well-nourished subjects, the interactive effect of dietary supplementation on muscle function appears limited.

1 January 2019 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
ESElizabeth J Samelson
Elizabeth J Samelson
KBKerry E Broe
Kerry E Broe
HXHanfei Xu
Hanfei Xu
LYLaiji Yang
Laiji Yang
SBSteven Boyd
Steven Boyd
MBMary L Bouxsein
Mary L Bouxsein

13 June 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MJMuhammad Kassim Javaid
Muhammad Kassim Javaid
ABAlison Boyce
Alison Boyce
NANatasha M. Appelman-Dijkstra
Natasha M. Appelman-Dijkstra
JOJuling Ong
Juling Ong
PDPatrizia Defabianis
Patrizia Defabianis
MCMichael Terrence Collins
Michael Terrence Collins
Fibrous Dysplasia / McCune Albright syndrome (FD/MAS) represents a wide spectrum of diseases due to somatic gain-of-function mutations of the GNAS gene. The mutation leads to overactivity in the target tissues and to a wide phenotype of clinical features that vary in severity and age of onset. The rarity of the disease and its variable presentation to multiple specialities often leads to misdiagnosis and inappropriate variability in investigations and treatments. To address this, our international consortium of clinicians, researchers, and patients’ advocates has developed pragmatic clinical guidelines for best clinical practice for the definition, diagnosis, staging, treatment and monitoring for FD/MAS to empower patients and support clinical teams in both general and specialised healthcare settings. With the lack of strong evidence to inform care, the guidelines were developed based on review of published literature, long-standing extensive experience of authors, input from other healthcare professionals involved in the care of FD/MAS patients and feedback from patients and patient groups across the globe. This has led to the formulation of a set of statements to inform healthcare professionals, patients, their families, carers and patient groups of the best practice of care. It is anticipated the implementation of these recommendations will lead to improvement in the care of patients with FD/MAS internationally.

1 August 2019 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
Nicola VeroneseNicola Veronese
Nicola Veronese
CCCyrus Cooper
Cyrus Cooper
JRJean-Yves Reginster
Jean-Yves Reginster
MHMarc Hochberg
Marc Hochberg
Jaime BrancoJaime Branco
Jaime Branco
ASAndré Scheen
André Scheen
Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the safety of anti-OA treatments in patients with T2DM. T2DM has a pathogenic effect on OA through 2 major pathways involving oxidative stress and low-grade chronic inflammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk factor for OA progression and has a negative impact on arthroplasty outcomes. Evidence is mounting for safety concerns with some of the most frequently prescribed anti-OA medications, including paracetamol, non-steroidal anti-inflammatory drugs, and corticosteroid injections, while other anti-OA medications may be safely prescribed in OA patients with T2DM, such as glucosamine and intra-articular hyaluronic acid. Future research is needed to better understand whether diabetes control and prevention can modulate OA occurrence and progression. The selection of therapy to treat OA symptoms in patients with T2DM may require careful consideration of the evidence based to avoid untoward safety issues.

1 April 2019 in Drugs & Aging
Verified
Journal Article
Open access
PDF file
CCCyrus Cooper
Cyrus Cooper
RCRoland Chapurlat
Roland Chapurlat
Nasser M Al-DaghriNasser M Al-Daghri
Nasser M Al-Daghri
GHGabriel Herrero-beaumont
Gabriel Herrero-beaumont
Olivier BruyèreOlivier Bruyère
Olivier Bruyère
Jean-Yves ReginsterJean-Yves Reginster
Jean-Yves Reginster
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely recommended and prescribed to treat pain in osteoarthritis. While measured to have a moderate effect on pain in osteoarthritis, NSAIDs have been associated with wide-ranging adverse events affecting the gastrointestinal, cardiovascular, and renal systems. Gastrointestinal toxicity is found with all NSAIDs, which may be of particular concern when treating older patients with osteoarthritis, and gastric adverse events may be reduced by taking a concomitant gastroprotective agent, although intestinal adverse events are not ameliorated. Cardiovascular toxicity is associated with all NSAIDs to some extent and the degree of risk appears to be pharmacotherapy specific. An increased risk of acute myocardial infarction and heart failure is observed with all NSAIDs, while an elevated risk of hemorrhagic stroke appears to be restricted to the use of diclofenac and meloxicam. All NSAIDs have the potential to induce acute kidney injury, and patients with osteoarthritis with co-morbid conditions including hypertension, heart failure, and diabetes mellitus are at increased risk. Osteoarthritis is associated with excess mortality, which may be explained by reduced levels of physical activity owing to lower limb pain, presence of comorbid conditions, and the adverse effects of anti-osteoarthritis medications especially NSAIDs. This narrative review of recent literature identifies data on the safety of non-selective NSAIDs to better understand the risk:benefit of using NSAIDs to manage pain in osteoarthritis.